Gossamer Bio(US:GOSS)2026-03-17 20:04Financial Performance - Total revenue for the fourth quarter of 2025 was $13.8 million, compared to $9.4 million for the same period in 2024, representing a 47.5% increase[16] - Net loss for Q4 2025 was $47.2 million, or $0.21 per share, compared to a net loss of $33.0 million, or $0.15 per share, for Q4 2024[12] - Total operating expenses for the full year 2025 were $219.2 million, compared to $174.6 million for 2024, reflecting a 25.5% increase[16] - The accumulated deficit as of December 31, 2025, was $1.44 billion, compared to $1.27 billion at the end of 2024[17] Research and Development - Research and Development (R&D) expenses for Q4 2025 were $48.9 million, up from $36.1 million in Q4 2024, marking a 35.5% increase[11] - In the PROSERA study, seralutinib showed a placebo-adjusted improvement in six-minute walk distance of approximately +13.3 meters at Week 24, although it did not meet the prespecified statistical threshold[6] Regulatory and Clinical Updates - The company plans to request a Type C meeting with the FDA in June 2026 to discuss the PROSERA dataset and potential regulatory paths forward[10] - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the company evaluates the implications of PROSERA results[5] Operational Changes - The company implemented a reduction in force to align resources with near-term priorities[8] - Cash, cash equivalents, and marketable securities totaled $136.9 million as of December 31, 2025, down from $294.5 million at the end of 2024[17]